Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo may ease stent pain better than standard care

NCT ID NCT07307261

Symptom relief Sponsor: Avraiem Talaat Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two drugs—mirabegron and tamsulosin—alone or together to relieve pain and urinary problems caused by ureteric stents. 300 adults who had a stent for the first time took part. The goal was to see which approach works best with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mirabegron and tamsulosin (drugs)
What this could lead to
If it works, this could give doctors a better option to reduce pain and urinary symptoms from ureteric stents, with fewer side effects than current treatments.
What could go wrong
This is a completed study, but results may not apply to everyone, and individual responses to the drugs can vary. Side effects like dizziness or low blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Oct 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First time to use Ureteric stent . Exclusion Criteria: * Urinary tract infection. * Previous ureteral surgery. * Congenital malformation of the ureter. * Distal ureteric stricture. * Hypersensitivity to the drugs. * Pregnancy or lactation. * Hepatic insufficiency * Non-compliant patients. * Age \< 18 years old .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ureteric stent-related morbidity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ureteric stent-related morbidity

Contacts and locations

Locations

  • Qena Hospital

    Qina, Egypt